A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Deepak Bhamidipati, MD
SCRI
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Healthone Denver
Denver, Colorado, United States
Recruiting - Florida Cancer Specialists
Orlando, Florida, United States
Recruiting - Scri Oncology Partners
Nashville, Tennessee, United States
Recruiting - Scri at Mary Crowley
Dallas, Texas, United States
Recruiting - Next Oncology
San Antonio, Texas, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Feb 2026
- Primary completion
- 31 Mar 2027
- Completion
- 31 Jan 2028
- Last update posted
- 12 Aug 2026
- Registered enrollment
- 14
- Registry id
- NCT07372625
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.